Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis

Fig. 4

Time to first severe SFI flare over 52 weeks. BLyS B lymphocyte stimulator, IFN interferon, IFN-1 type 1 IFN-inducible gene signature, mRNA messenger ribonucleic acid, SELENA-SLEDAI Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index, SFI SELENA-SLEDAI Flare Index

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us